Phase II Study of the Combination of Pembrolizumab, Letrozole and Palbociclib in Postmenopausal Patients With Newly Diagnosed Metastatic Estrogen Receptor Positive Breast Cancer

Trial Profile

Phase II Study of the Combination of Pembrolizumab, Letrozole and Palbociclib in Postmenopausal Patients With Newly Diagnosed Metastatic Estrogen Receptor Positive Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Letrozole (Primary) ; Palbociclib (Primary) ; Pembrolizumab (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jun 2017 Planned number of patients changed from 18 to 22.
    • 30 Sep 2016 Planned primary completion date changed from 1 Jul 2018 to 1 Sep 2018.
    • 30 Sep 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top